AU Patent

AU2019252790A1 — Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion

Assigned to Jazz Pharmaceuticals Inc · Expires 2020-10-15 · 6y expired

What this patent protects

The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the im…

USPTO Abstract

The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019252790A1
Jurisdiction
AU
Classification
—
Expires
2020-10-15
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.